Supernus Pharmaceuticals (SUPN) Other Non Operating Income (2011 - 2025)
Supernus Pharmaceuticals (SUPN) posted quarterly Other Non Operating Income of $2.0 million for Q4 2025, down 59.35% year-over-year from $5.0 million in Q4 2024, and down 11.16% on a QoQ basis from $2.3 million in Q3 2025.
Supernus Pharmaceuticals (SUPN) Other Non Operating Income (2011 - 2025) Analysis & Trends
Supernus Pharmaceuticals has reported Other Non Operating Income for 15 years, with the latest figure at $2.0 million in Q4 2025.
- Other Non Operating Income for Q4 2025 came in at $2.0 million, down 59.35% year-over-year; the trailing twelve-month figure through Dec 2025 was $13.3 million (down 18.21% YoY), and the FY2025 annual result was $13.3 million, down 18.21% from the prior year.
- Other Non Operating Income retreated to $2.0 million in Q4 2025, from $2.3 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $14.7 million in Q1 2022 and troughed at -$21.5 million in Q4 2021.
- A 5-year average of $2.4 million and a median of $2.7 million in 2021 frame the typical range for Other Non Operating Income.
- The widest annual swing landed in 2021, when Other Non Operating Income sank 871.62%; it then jumped 285.57% in 2022.
- A 5-year view of Other Non Operating Income shows it stood at -$21.5 million in 2021, then surged by 111.14% to $2.4 million in 2022, then declined by 17.25% to $2.0 million in 2023, then soared by 150.6% to $5.0 million in 2024, then tumbled by 59.35% to $2.0 million in 2025.
- Per Business Quant data, the three most recent Other Non Operating Income figures were $2.0 million in Q4 2025, $2.3 million in Q3 2025, and $4.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.73 Bn | 2.36 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.02 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 4.53 Mn |
| Mar 31, 2025 | 4.43 Mn |
| Dec 31, 2024 | 4.98 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 3.73 Mn |
| Mar 31, 2024 | 3.40 Mn |
| Dec 31, 2023 | 1.99 Mn |
| Sep 30, 2023 | 1.75 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | 5.35 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 1.79 Mn |
| Mar 31, 2022 | 14.70 Mn |
| Dec 31, 2021 | -21.54 Mn |
| Sep 30, 2021 | 2.28 Mn |
| Jun 30, 2021 | 2.59 Mn |
| Mar 31, 2021 | 3.81 Mn |